JP2008540390A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540390A5 JP2008540390A5 JP2008509501A JP2008509501A JP2008540390A5 JP 2008540390 A5 JP2008540390 A5 JP 2008540390A5 JP 2008509501 A JP2008509501 A JP 2008509501A JP 2008509501 A JP2008509501 A JP 2008509501A JP 2008540390 A5 JP2008540390 A5 JP 2008540390A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- methoxy
- group
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- -1 cyano, cyclopropyl Chemical group 0.000 claims 11
- 125000001153 fluoro group Chemical group F* 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000006413 ring segment Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 3
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims 2
- 125000004185 ester group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 150000003568 thioethers Chemical class 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000013392 Carboxylesterase Human genes 0.000 claims 1
- 108010051152 Carboxylesterase Proteins 0.000 claims 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 1
- 230000009702 cancer cell proliferation Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- XASGFOVGTYZBNT-AREMUKBSSA-N cyclopentyl (2r)-2-amino-4-[4-(4-benzamidophenoxy)-6-methoxyquinolin-7-yl]oxybutanoate Chemical compound C1=CN=C2C=C(OCC[C@@H](N)C(=O)OC3CCCC3)C(OC)=CC2=C1OC(C=C1)=CC=C1NC(=O)C1=CC=CC=C1 XASGFOVGTYZBNT-AREMUKBSSA-N 0.000 claims 1
- GMLQSURAAMXEPL-AREMUKBSSA-N cyclopentyl (2r)-2-amino-4-[6-methoxy-4-[4-[[4-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]quinolin-7-yl]oxybutanoate Chemical compound C1=CN=C2C=C(OCC[C@@H](N)C(=O)OC3CCCC3)C(OC)=CC2=C1OC(C=C1)=CC=C1NC(=O)NC1=CC=C(C(F)(F)F)C=C1 GMLQSURAAMXEPL-AREMUKBSSA-N 0.000 claims 1
- HQMGHFHGJNVQEY-HHHXNRCGSA-N cyclopentyl (2r)-2-amino-5-[4-(4-benzamidophenoxy)-6-methoxyquinolin-7-yl]oxypentanoate Chemical compound C1=CN=C2C=C(OCCC[C@@H](N)C(=O)OC3CCCC3)C(OC)=CC2=C1OC(C=C1)=CC=C1NC(=O)C1=CC=CC=C1 HQMGHFHGJNVQEY-HHHXNRCGSA-N 0.000 claims 1
- MTKVXKVFYORTSH-HHHXNRCGSA-N cyclopentyl (2r)-2-amino-5-[6-methoxy-4-[4-[[4-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]quinolin-7-yl]oxypentanoate Chemical compound C1=CN=C2C=C(OCCC[C@@H](N)C(=O)OC3CCCC3)C(OC)=CC2=C1OC(C=C1)=CC=C1NC(=O)NC1=CC=C(C(F)(F)F)C=C1 MTKVXKVFYORTSH-HHHXNRCGSA-N 0.000 claims 1
- XASGFOVGTYZBNT-SANMLTNESA-N cyclopentyl (2s)-2-amino-4-[4-(4-benzamidophenoxy)-6-methoxyquinolin-7-yl]oxybutanoate Chemical compound C1=CN=C2C=C(OCC[C@H](N)C(=O)OC3CCCC3)C(OC)=CC2=C1OC(C=C1)=CC=C1NC(=O)C1=CC=CC=C1 XASGFOVGTYZBNT-SANMLTNESA-N 0.000 claims 1
- UVTSZJWVVSNSQW-VWLOTQADSA-N cyclopentyl (2s)-2-amino-4-[4-[2-fluoro-4-[[4-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-6-methoxyquinolin-7-yl]oxybutanoate Chemical compound C1=CN=C2C=C(OCC[C@H](N)C(=O)OC3CCCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)NC1=CC=C(C(F)(F)F)C=C1 UVTSZJWVVSNSQW-VWLOTQADSA-N 0.000 claims 1
- VWXNDFYKRGBELN-SANMLTNESA-N cyclopentyl (2s)-2-amino-4-[4-[4-[(4-chlorobenzoyl)amino]phenoxy]-6-methoxyquinolin-7-yl]oxybutanoate Chemical compound C1=CN=C2C=C(OCC[C@H](N)C(=O)OC3CCCC3)C(OC)=CC2=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C=C1 VWXNDFYKRGBELN-SANMLTNESA-N 0.000 claims 1
- FAGSHAYSFQEJAD-SANMLTNESA-N cyclopentyl (2s)-2-amino-4-[6-methoxy-4-[4-(phenylcarbamoylamino)phenoxy]quinolin-7-yl]oxybutanoate Chemical compound C1=CN=C2C=C(OCC[C@H](N)C(=O)OC3CCCC3)C(OC)=CC2=C1OC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1 FAGSHAYSFQEJAD-SANMLTNESA-N 0.000 claims 1
- HQMGHFHGJNVQEY-MHZLTWQESA-N cyclopentyl (2s)-2-amino-5-[4-(4-benzamidophenoxy)-6-methoxyquinolin-7-yl]oxypentanoate Chemical compound C1=CN=C2C=C(OCCC[C@H](N)C(=O)OC3CCCC3)C(OC)=CC2=C1OC(C=C1)=CC=C1NC(=O)C1=CC=CC=C1 HQMGHFHGJNVQEY-MHZLTWQESA-N 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0509227.5A GB0509227D0 (en) | 2005-05-05 | 2005-05-05 | Intracellular enzyme inhibitors |
| PCT/GB2006/001609 WO2006117552A1 (en) | 2005-05-05 | 2006-05-04 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540390A JP2008540390A (ja) | 2008-11-20 |
| JP2008540390A5 true JP2008540390A5 (enExample) | 2009-06-18 |
Family
ID=34685159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008509501A Pending JP2008540390A (ja) | 2005-05-05 | 2006-05-04 | キナーゼ酵素活性阻害剤としてのキノリン及びキノキサリン誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8148531B2 (enExample) |
| EP (1) | EP1877383B1 (enExample) |
| JP (1) | JP2008540390A (enExample) |
| KR (1) | KR20080010400A (enExample) |
| CN (1) | CN101166726A (enExample) |
| AT (1) | ATE523492T1 (enExample) |
| AU (1) | AU2006243068B2 (enExample) |
| BR (1) | BRPI0609857A2 (enExample) |
| CA (1) | CA2606338A1 (enExample) |
| GB (1) | GB0509227D0 (enExample) |
| IL (1) | IL186551A0 (enExample) |
| MX (1) | MX2007013276A (enExample) |
| NZ (1) | NZ562520A (enExample) |
| WO (1) | WO2006117552A1 (enExample) |
| ZA (1) | ZA200709304B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005293336B2 (en) | 2004-10-12 | 2009-05-28 | Astrazeneca Ab | Quinazoline derivatives |
| CA2607020C (en) * | 2005-05-05 | 2015-01-13 | Chroma Therapeutics Ltd. | Alpha amino acid ester-drug conjugates hydrolysable by carboxylesterases |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| CA2655128A1 (en) * | 2006-06-08 | 2007-12-21 | Array Biopharma Inc. | Quinoline compounds and methods of use |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
| BRPI0622100A2 (pt) * | 2006-10-30 | 2011-12-27 | Chroma Therapeutics Ltd | hidroxamatos como inibidores de desacetilase de histona |
| GB0803747D0 (en) | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
| JP5746015B2 (ja) * | 2008-04-16 | 2015-07-08 | マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー | Ａｘｌキナーゼ阻害剤としてのキノリン誘導体 |
| GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| EP2311809A1 (en) * | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
| JP2011241170A (ja) * | 2010-05-18 | 2011-12-01 | Mercian Corp | ビタミンｄ誘導体およびその製造方法 |
| RU2449988C1 (ru) * | 2011-04-29 | 2012-05-10 | Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран) | 2,2,2-трифтор-1-трифторметилэтиловый эфир циклогексилкарбаминовой кислоты в качестве эффективного средства для селективного необратимого ингибирования карбоксилэстеразы |
| WO2013032951A1 (en) | 2011-08-26 | 2013-03-07 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| EP3332785B1 (en) | 2011-09-14 | 2020-05-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| EP2757885B1 (en) * | 2011-09-21 | 2017-03-15 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
| US9249111B2 (en) | 2011-09-30 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-RAF kinase inhibitors |
| EP2806874B1 (en) | 2012-01-25 | 2017-11-15 | Neupharma, Inc. | Quinoxaline-oxy-phenyl derivatives as kinase inhibitors |
| TWI485146B (zh) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
| CN103304489B (zh) * | 2012-03-16 | 2015-03-11 | 中国农业科学院兰州畜牧与兽药研究所 | 嘧啶苯甲酰胺类化合物及其制备和应用 |
| LT2864291T (lt) | 2012-06-26 | 2017-01-10 | Bayer Pharma Aktiengesellschaft | N-[4-(chinolin-4-iloksi)cikloheksil(metil)](hetero)arilkarboksamidai kaip androgeno receptoriaus antagonistai, jų gamyba ir panaudojimas kaip medicininių produktų |
| GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| CN104812389B (zh) | 2012-09-24 | 2020-07-17 | 润新生物公司 | 某些化学实体、组合物及方法 |
| PT3222616T (pt) | 2012-10-17 | 2019-09-26 | Macrophage Pharma Ltd | N-[2-{4-[6-amino-5-(2,4-difluorobenzoíl)-2-oxopiridin-l(2h)-il]-3,5-difluorofenil}etil)-l-alaninato e o éster de terc-butilo do mesmo |
| WO2014075077A1 (en) | 2012-11-12 | 2014-05-15 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CN103965107B (zh) * | 2013-02-06 | 2016-08-17 | 沈阳药科大学 | 2-芳基取代喹啉类化合物及其用途 |
| HK1217092A1 (zh) | 2013-02-15 | 2016-12-23 | Kala Pharmaceuticals, Inc. | 治疗性化合物及其用途 |
| BR112015020139A2 (pt) | 2013-02-20 | 2017-07-18 | Kala Pharmaceuticals Inc | compostos terapêuticos e usos dos mesmos |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| PL3018165T3 (pl) * | 2013-07-01 | 2019-11-29 | Lg Chemical Ltd | Związek poliorganosiloksanowy, sposób jego wytwarzania i zawierająca go żywica kopoliwęglanowa |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
| CN104072492A (zh) * | 2013-11-27 | 2014-10-01 | 苏州摩尔医药有限公司 | 一种抗肿瘤靶向治疗药物Tivozanib的合成方法 |
| CN105085433B (zh) * | 2014-05-19 | 2019-06-25 | 中国科学院上海药物研究所 | 取代酰胺苯酚类化合物及其制备方法、药物组合物和用途 |
| MY187540A (en) | 2014-08-01 | 2021-09-28 | Nuevolution As | Compounds active towards bromodomains |
| WO2017062500A2 (en) | 2015-10-05 | 2017-04-13 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
| US10550135B2 (en) | 2016-03-30 | 2020-02-04 | Council Of Scientific & Industrial Research | Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity |
| CN106083715A (zh) * | 2016-06-01 | 2016-11-09 | 谢阳 | 一种喹啉、喹唑啉类化合物及其药物组合物和应用 |
| CA3036336A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA3036065A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| CA3039919A1 (en) * | 2016-10-10 | 2018-04-19 | Development Center For Biotechnology | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors |
| GB201713975D0 (en) | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
| CN111303024B (zh) * | 2018-12-12 | 2023-03-28 | 安徽中科拓苒药物科学研究有限公司 | 一种喹啉结构的pan-KIT激酶抑制剂及其用途 |
| CN112778217B (zh) * | 2019-11-08 | 2024-01-26 | 沈阳化工研究院有限公司 | 一种喹唑啉类化合物及其应用 |
| US20240270683A1 (en) * | 2021-06-17 | 2024-08-15 | Chandrasekhar Dayal Mudaliar | A process for preparation of an intermediate of l-glufosinate |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997017329A1 (en) * | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| US6448256B1 (en) * | 1999-05-24 | 2002-09-10 | University Of Massachusetts | Antibiotic prodrugs |
| CN1391562A (zh) * | 1999-09-21 | 2003-01-15 | 阿斯特拉曾尼卡有限公司 | 用作药物的喹唑啉衍生物 |
| GB9922171D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| EE200200715A (et) | 2000-06-28 | 2004-08-16 | Astrazeneca Ab | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena |
| PL370137A1 (en) * | 2001-11-27 | 2005-05-16 | Wyeth Holdings Corporation | 3-cyanoquinolines as inhibitors of egf-r and her2 kinases |
| TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| PA8603801A1 (es) * | 2003-05-27 | 2004-12-16 | Janssen Pharmaceutica Nv | Derivados de la quinazolina |
| EP1670786A1 (en) * | 2003-09-25 | 2006-06-21 | Astrazeneca AB | Quinazoline derivatives |
| WO2005097134A2 (en) * | 2004-03-31 | 2005-10-20 | The Scripps Research Institute | Quinazoline based protein kinase inhibitors |
| US7732613B2 (en) * | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
-
2005
- 2005-05-05 GB GBGB0509227.5A patent/GB0509227D0/en not_active Ceased
-
2006
- 2006-05-04 NZ NZ562520A patent/NZ562520A/en not_active IP Right Cessation
- 2006-05-04 EP EP06726986A patent/EP1877383B1/en not_active Not-in-force
- 2006-05-04 BR BRPI0609857-6A patent/BRPI0609857A2/pt not_active IP Right Cessation
- 2006-05-04 MX MX2007013276A patent/MX2007013276A/es active IP Right Grant
- 2006-05-04 JP JP2008509501A patent/JP2008540390A/ja active Pending
- 2006-05-04 CN CNA2006800146825A patent/CN101166726A/zh active Pending
- 2006-05-04 US US11/918,898 patent/US8148531B2/en not_active Expired - Fee Related
- 2006-05-04 KR KR1020077024927A patent/KR20080010400A/ko not_active Ceased
- 2006-05-04 AT AT06726986T patent/ATE523492T1/de not_active IP Right Cessation
- 2006-05-04 AU AU2006243068A patent/AU2006243068B2/en not_active Ceased
- 2006-05-04 CA CA002606338A patent/CA2606338A1/en not_active Abandoned
- 2006-05-04 WO PCT/GB2006/001609 patent/WO2006117552A1/en not_active Ceased
-
2007
- 2007-10-10 IL IL186551A patent/IL186551A0/en unknown
- 2007-10-29 ZA ZA200709304A patent/ZA200709304B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540390A5 (enExample) | ||
| JP2010507639A5 (enExample) | ||
| JP2010505802A5 (enExample) | ||
| WO2006124490A3 (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| YU58701A (sh) | Derivati tioamida | |
| EP1180030B1 (en) | Antibacterial compounds | |
| WO2024076670A3 (en) | Tethered heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| HUP0200207A2 (hu) | Helyettesített 2-aril-(heteroaril)-imidazo [1,2-a]pirimidin-származékok, előállításuk és az ezeket tartalmazó gyógyszerkészítmények | |
| MXPA03009649A (es) | Heteroaril ureas que contienen hetero-atomos de nitrogeno como inhibidores de p38 cinasa. | |
| TW200738729A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| JP2018511631A5 (enExample) | ||
| CA2471642A1 (en) | 6-fluorobicyclo[3.1.0]hexane derivatives | |
| NZ594493A (en) | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors | |
| MY129000A (en) | INHIBITORS OF a4 MEDIATED CELL ADHESION | |
| JP2007016035A5 (enExample) | ||
| JP2004529161A5 (enExample) | ||
| JP2008505120A5 (enExample) | ||
| CA2392570A1 (en) | 4-pyrimidinyl-n-acyl-l-phenylalanines | |
| WO2008087611A3 (en) | Pyrrolidine- and piperidine- bis-amide derivatives | |
| RU2014153423A (ru) | Производные 2-аминопиразина в качестве ингибиторов csf-1r киназы | |
| JP2009535387A5 (enExample) | ||
| JP2013542980A5 (enExample) | ||
| JP2012524110A5 (enExample) | ||
| Bolos | Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors | |
| Borzilleri et al. | Synthesis and SAR of 4-(3-hydroxyphenylamino) pyrrolo [2, 1-f][1, 2, 4] triazine based VEGFR-2 kinase inhibitors |